TSX:PMN (Canada)
Business Description
ProMIS Neurosciences Inc
NAICS : 325412
SIC : 3741
1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
Compare
Compare
Traded in other countries / regions
PMN.Canada
•
23J0.Germany
•
PMN.USA
Description
ProMIS Neurosciences Inc is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company also plans to investigate additional synucleionapathies, including Parkinson's disease, and dementia with Lewy bodies. It primarily operates in Canada.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.41 | |||||
| Equity-to-Asset | 0.26 | |||||
| Debt-to-Equity | 1.08 | |||||
| Debt-to-EBITDA | -0.78 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -4.35 | |||||
| Beneish M-Score | 2.24 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 8.8 | |||||
| 3-Year EPS without NRI Growth Rate | 9.1 | |||||
| 3-Year FCF Growth Rate | 1.9 | |||||
| 3-Year Book Growth Rate | 54.6 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.38 | |||||
| 9-Day RSI | 56.96 | |||||
| 14-Day RSI | 53.96 | |||||
| 6-1 Month Momentum % | 45.33 | |||||
| 12-1 Month Momentum % | -16.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.37 | |||||
| Quick Ratio | 10.37 | |||||
| Cash Ratio | 9.92 | |||||
| Days Sales Outstanding | 3923.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.5 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -100253.33 | |||||
| Net Margin % | -48426.67 | |||||
| ROE % | -848.2 | |||||
| ROA % | -41.78 | |||||
| ROIC % | -1685.12 | |||||
| ROC (Joel Greenblatt) % | -5333.88 | |||||
| ROCE % | -41.75 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2666.65 | |||||
| PB Ratio | 12.33 | |||||
| Price-to-Tangible-Book | 12.5 | |||||
| EV-to-EBIT | -6.93 | |||||
| EV-to-EBITDA | -6.98 | |||||
| EV-to-Revenue | 3026.8 | |||||
| EV-to-FCF | -2.81 | |||||
| Price-to-Net-Current-Asset-Value | 12.5 | |||||
| Price-to-Net-Cash | 14.81 | |||||
| Earnings Yield (Greenblatt) % | -14.43 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 0.015 | ||
| EPS (TTM) (C$) | -0.821 | ||
| Beta | 1.58 | ||
| Volatility % | 38.17 | ||
| 14-Day RSI | 53.96 | ||
| 14-Day ATR (C$) | 0.590361 | ||
| 20-Day SMA (C$) | 7.816 | ||
| 12-1 Month Momentum % | -16.74 | ||
| 52-Week Range (C$) | 5.699999 - 16.199999 | ||
| Shares Outstanding (Mil) | 7.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ProMIS Neurosciences Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||